Announcement of the death of Mr. Jacques DIKANSKY, Founder of NATUREX
Avignon, 1st October 2012
It is with great sadness that Naturex announces the passing of its Chairman and Founder, Mr. Jacques Dikansky, this weekend after a long period of illness, surrounded by his children and family.
A true entrepreneurial spirit and a talented visionary, Jacques Dikansky was a source of inspiration for his employees with whom he shared his passion for the industry of plant-based natural ingredients for more than 20 years. His keen sense of strategy and the quality of the acquisitions he successfully completed contributed to transforming Naturex over this period into the global leader in speciality plant-based natural ingredients.
All Naturex's 1,300 employees join the members of the Management Committee and the Board of Directors of the Company in expressing their sincerest condolences to Mr. Jacques Dikansky's family and close relations.
NATUREX is the world leader in specialty plant-based ingredients.
The Group, organised around three strategic markets - Food & Beverage, Nutrition & Health and Personal Care -, produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetics industries.
NATUREX's head office is based in Avignon. Naturex employs over 1,300 people and has high-performance industrial resources across its 15 industrial sites in Europe (France, Italy, Spain, United Kingdom, Switzerland and Poland), in Morocco, the United States, Brazil, Australia and India. The company draws on its worldwide sales presence through a fully dedicated sales network in 21 countries (France, Italy, Spain, Morocco, United Kingdom, Belgium, Germany, Poland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, United States, Canada, Brazil, Mexico, India).
NATUREX enjoys the highly favourable underlying trend linked to increasing demand for natural-origin products and provides manufacturers with personalised solutions in order to meet the expectations of the end consumers. The force of the Group resides in its positioning on specific products that form market niches, thanks to a strong sourcing capacity and support for Research and Development.
You can receive all of NATUREX's financial information free of charge by signing up on:
|- Q3 2012 revenue
||5 November 2012
|- Q3 2012 results
||29 November 2012
|- Annual revenue 2012
||24 January 2013
|- Annual results 2012
||27 March 2013
Naturex has been listed since October 1996 on NYSE Euronext in Paris, compartment B
Number of shares comprising the capital: 7,728,079
- 6,968,924 ordinary shares (ISIN FR0000054694)
- 759,155 preferred shares (ISIN FR0010833251)
Naturex is part of the CAC Small and Gaïa Indexes.
Naturex is eligible for "long only" Deferred Settlement Service (SRD).
Naturex has set up a sponsored level I American Depositary Receipt (ADR) programme. Naturex's ADRs are traded over the counter in the United States under the symbol NTUXY.
MNEMO: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP - DR Symbol: NTUXY